A facilitated approach to evaluate the inhibitor mode and potency of compounds targeting microsomal prostaglandin e synthase-1

Assay and Drug Development Technologies

Volumn 9, Issue 5, 2011, Pages 487-495

  Spahiu, Linda ^a   Stenberg, Patric ^a,b   Larsson, Charlotte ^a   Wannberg, Johan ^a   Alterman, Mathias ^a   Kull, Björn ^a   Nekhotiaeva, Natalia ^a   Morgenstern, Ralf ^a,b,c  

^a Actar AB   (Sweden)

^b Nova SAID AB   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; GLUTATHIONE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN H2; THIOBARBITURIC ACID;

ARTICLE; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; IC 50;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; FLUORESCENCE; GLUTATHIONE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; INTRAMOLECULAR OXIDOREDUCTASES; MALONDIALDEHYDE; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; PHARMACOKINETICS; PROSTAGLANDIN H2; THIOBARBITURATES;

EID: 80052251883     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0350     Document Type: Article

References (44)

1. Simmons D, Botting R, Hla T: Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.
2. Smith W, Marnett L, DeWitt D: Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991;49:153-179.
3. Funk CD: Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001;294:1871-1875.
4. Yamada T, Takusagawa F: PGH2 degradation pathway catalyzed by GSH-heme complex bound microsomal prostaglandin E2 synthase type 2: The first example of a dual-function enzyme. Biochemistry 2007;46:8414-8424.
5. Granström E, Hamberg M, Hansson G, Kindahl H: Chemical instability of 15- keto-13,14-dihydro-PGE2: The reason for low assay reliability. Prostaglandins 1980;19:933-957.
6. Fitzpatrick F, Aguirre R, Pike J, Lincoln F: The stability of 13,14-dihydro-15 keto- PGE2. Prostaglandins 1980;19:917-931.
7. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I: Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-32782.
8. Murakami M, Naraba H, Tanioka T, et al.: Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275:32783-32792.
9. Samuelsson B, Morgenstern R, Jakobsson PJ: Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 2007;59:207-224.
10. Oshima H, Matsunaga A, Fujimura T, Tsukamoto T, Taketo M, Oshima M: Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology 2006;131:1086-1095.
11. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: A role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 2006;5:62.
12. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S: Microsomal prostaglandin E2 synthase-1 in breast cancer: A potential target for therapy. J Pathol 2006;208:356-363.
13. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y: Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci U S A 2006;103:11790-11795.
14. Hofstetter A, Saha S, Siljehav V, Jakobsson P, Herlenius E: The induced prostaglandin E2 pathway is a key regulator of the respiratory response to infection and hypoxia in neonates. Proc Natl Acad Sci U S A 2007;104:9894-9899.
15. El-Asrar A, Missotten L, Geboes K: Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2008;92:1534-1539.
16. Martey C, Pollock S, Turner C, et al.: Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: Implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004;287:L981-L991.
17. Takeda H, Sonoshita M, Oshima H, et al.: Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003;63:4872-4877.
18. Chell S, Kaidi A, Kadi A, Williams A, Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 2006;1766: 104-119.
19. Butovich I, Lukyanova S: Inhibition of lipoxygenases and cyclooxygenases by linoleyl hydroxamic acid: Comparative in vitro studies. J Lipid Res 2008;49: 1284-1294.
20. Elander N, Zhou J, Ungerbäck J, Dimberg J, Söderkvist P: Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer. Mol Carcinog 2009;48:401-407.
21. Chaudhry U, Zhuang H, Crain B, Doré S: Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease. Alzheimers Dement 2008;4:6-13.
22. Thoren S, Weinander R, Saha S, et al.: Human microsomal prostaglandin E synthase-1: Purification, functional characterization, and projection structure determination. J Biol Chem 2003;278:22199-22209.
23. Ouellet M, Falgueyret J, Ear P, et al. Purification and characterization of recombinant microsomal prostaglandin E synthase-1. Protein Expr Purif 2002;26:489-495.
24. Huang X, Yan W, Gao D, Tong M, Tai H, Zhan C: Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. Bioorg Med Chem 2006;14:3553-3562.
25. Holm P, Bhakat P, Jegerschöld C, et al.: Structural basis for detoxification and oxidative stress protection in membranes. J Mol Biol 2006;360:934-945.
26. Martinez Molina D, Wetterholm A, Kohl A, et al.: Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007;448:613-616.
27. Ago H, Kanaoka Y, Irikura D, et al.: Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007;448:609-612.
28. Ferguson A, McKeever B, Xu S, et al.: Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007;317:510-512.
29. Kim W, Choi K, Do H, Yu Y: Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library. BMB Rep 2008;41:808-813.
30. Xing L, Kurumbail R, Frazier R, et al.: Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/ inhibitor binding interactions. J Comput Aided Mol Des 2009;23:13-24.
31. Jegerschöld C, Pawelzik S, Purhonen P, et al.: Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci U S A 2008;105:11110-11115.
32. Xu D, Rowland S, Clark P, et al.: MF63 [2-(6-chloro-1H-phenanthro[9,10- d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther 2008;326:754-763.
33. Pawelzik S, Uda N, Spahiu L, et al.: Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin e synthase-1. J Biol Chem 2010; 285:29254-29261.
34. Basevich VV, Mevkh AT, Varfolomeev SD: [Kinetics of prostaglandin H2 degradation. A method of determining prostaglandin H-convertase activity]. Bioorg Khim 1983;9:658-665.
35. Placer ZA, Cushman LL, Johnson BC: Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 1966;16:359-364.
36. Niehaus WG Jr., Samuelsson B: Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968;6: 126-130.
37. Copeland RA: Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, John Wiley & Sons, Incorporated, New Jersey, 2000.
38. Duggleby R, Clarke R: Experimental designs for estimating the parameters of the Michaelis-Menten equation from progress curves of enzyme-catalyzed reactions. Biochim Biophys Acta 1991;1080:231-236.
39. Gutierrez O, Danielson U: Sensitivity analysis and error structure of progress curves. Anal Biochem 2006;358:1-10.
40. Cortés A, Cascante M, Cárdenas M, Cornish-Bowden A: Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: New ways of analysing data. Biochem J 2001;357: 263-268.
41. Riendeau D, Aspiotis R, Ethier D, et al.: Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 2005;15:3352-3355.
42. Andersson C, Piemonte F, Mosialou E, et al.: Kinetic studies on rat liver microsomal glutathione transferase: Consequences of activation. Biochim Biophys Acta 1995;1247:277-283.
43. Yang J, Copeland R, Lai Z: Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J Biomol Screen 2009;14:111-120.
44. Griffith O: Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 1999;27:922-935.